- Home
- AEON vs HEPA Comparison
AEON vs HEPA Comparison
Compare AEON & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- HEPA
- Stock Information
- Founded
- AEON N/A
- HEPA 2013
- Country
- AEON United States
- HEPA United States
- Employees
- AEON N/A
- HEPA N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- HEPA Health Care
- Exchange
- AEON Nasdaq
- HEPA Nasdaq
- Market Cap
- AEON 744.2K
- HEPA 863.9K
- IPO Year
- AEON N/A
- HEPA N/A
- Fundamental
- Price
- AEON $0.59
- HEPA $0.49
- Analyst Decision
- AEON Strong Buy
- HEPA
- Analyst Count
- AEON 1
- HEPA 0
- Target Price
- AEON $360.00
- HEPA N/A
- AVG Volume (30 Days)
- AEON 8.4M
- HEPA 4.6M
- Earning Date
- AEON 03-24-2025
- HEPA 05-20-2025
- Dividend Yield
- AEON N/A
- HEPA N/A
- EPS Growth
- AEON N/A
- HEPA N/A
- EPS
- AEON 72.93
- HEPA N/A
- Revenue
- AEON N/A
- HEPA N/A
- Revenue This Year
- AEON N/A
- HEPA N/A
- Revenue Next Year
- AEON N/A
- HEPA N/A
- P/E Ratio
- AEON $0.01
- HEPA N/A
- Revenue Growth
- AEON N/A
- HEPA N/A
- 52 Week Low
- AEON $0.40
- HEPA $0.40
- 52 Week High
- AEON $626.40
- HEPA $145.00
- Technical
- Relative Strength Index (RSI)
- AEON 24.66
- HEPA 20.63
- Support Level
- AEON $0.61
- HEPA $0.40
- Resistance Level
- AEON $0.74
- HEPA $0.85
- Average True Range (ATR)
- AEON 0.09
- HEPA 0.18
- MACD
- AEON 0.47
- HEPA 0.30
- Stochastic Oscillator
- AEON 13.62
- HEPA 5.31
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.